This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer (NCT04015336), a na phase 2 study. The primary outcome is Fraction of Participants Who Can Receive Induction Therapy With E7 T-Cell Receptor (TCR) Cells Without Failing the Feasibility Criteria.
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04015336 |
| Phase | Phase 2 |
| Condition | Papillomavirus Infections, Oropharyngeal Neoplasms |
| Allocation | Not applicable (single group) |
| Design model | Single Group |
| Masking | None (open label) |
| Enrollment | 1 |
| Arms in the primary outcome | n/a |
| Lead sponsor | National Cancer Institute (NCI) |
| Results posted | Yes |
2. Clinical Question
Population
Adults with stage II or stage III HPV-16-associated oropharyngeal cancer were the intended population. Eligibility involved HLA typing and testing the tumor for HPV-16. The registry record states that the sole enrolled participant signed consent but was later deemed a screen failure and could not receive the study treatment.
Intervention
The study intervention was E7 T-cell receptor (TCR) T-cell induction immunotherapy. The registry describes intravenous administration of up to 3x10^10 E7 TCR T cells, with the amount based on the number of cells that could be generated using the shortened manufacturing process.
Comparator
This was a single-group study, with no comparator group recorded. The registry record does not describe a randomized or like-for-like control comparison. Standard treatment, which may involve surgery or radiation therapy with chemotherapy, is described as subsequent definitive care, not as a comparison arm.
Primary question
The study planned to assess whether participants could receive E7 TCR T-cell induction therapy without failing specified feasibility criteria over 3 months. Those criteria concerned tumor stage progression before referral for definitive treatment, treatment delay related to induction-therapy toxicity, and starting conditioning chemotherapy without subsequently receiving the T cells. The outcome was not collected because the participant was not treated.
3. Trial Design
The registry identifies this as a phase II, single-group study of E7 TCR T-cell induction immunotherapy for stage II and stage III HPV-associated oropharyngeal cancer. The study focused on HPV-16-associated disease. No masking was recorded, and allocation is listed as not applicable. The registry describes an intended treatment arm rather than a randomized comparison with a control group.
The intervention was E7 TCR T cells, administered intravenously over 20 to 30 minutes on day 0. The planned amount was up to 3x10^10 cells, depending on the number that could be generated by the shortened manufacturing process. The study’s stated objective was to determine whether the induction therapy could be given safely without delaying standard treatment. Standard treatment was described as surgery or radiation therapy with chemotherapy.
Screening was to include HLA typing and tumor testing to determine whether the cancer was HPV-16 positive. A new biopsy might be needed if tumor tissue from an outside location was unavailable for HPV testing. The registry also describes a screening evaluation at the NIH campus, including physical examination and review of medical history and current medications.
The registry reports enrollment of 1 and a terminated status. The study started on 2020-07-06, and primary completion is recorded as 2020-07-15. The participant signed consent but was later deemed a screen failure and did not receive induction therapy. The registry does not report a completed treatment cohort or a treatment comparison.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Overall Study
| Stage | Arm 1-3x10^10 E7 T-Cell Receptor (TCR) T Cells |
|---|---|
| STARTED | 1 |
| COMPLETED | 0 |
| NOT COMPLETED | 1 |
Reasons for not completing this period:
| Reason | Arm 1-3x10^10 E7 T-Cell Receptor (TCR) T Cells |
|---|---|
| Participant signed consent and was later deemed a screen failure. Participant was not treated | 1 |
Analysis population for the primary outcome, as defined in the registry: Data was not collected for this outcome measure. This outcome measure was not done because the single enrolled participant signed consent and was later deemed a screen failure, thus was unable to receive induction therapy with E7 TCR cells. Participant was not treated and the study was terminated due to logistical challenges.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Arm 1-3x10^10 E7 T-Cell Receptor (TCR) T Cells |
|---|---|---|
| Participants analysed | 1 | |
| Age, Categorical: <=18 years | Participants | 0 |
| Age, Categorical: Between 18 and 65 years | Participants | 1 |
| Age, Categorical: >=65 years | Participants | 0 |
| Age, Continuous | years | 59.1 (SD 0) |
| Sex: Female, Male: Female | Participants | 0 |
| Sex: Female, Male: Male | Participants | 1 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 0 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 1 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 0 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 0 |
| Race (NIH/OMB): Asian | Participants | 0 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 0 |
| Race (NIH/OMB): Black or African American | Participants | 0 |
| Race (NIH/OMB): White | Participants | 1 |
| Race (NIH/OMB): More than one race | Participants | 0 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 0 |
| Region of Enrollment: United States | participants | 1 |
6. Primary Endpoint
The registry lists the primary outcome as Fraction of Participants Who Can Receive Induction Therapy With E7 T-Cell Receptor (TCR) Cells Without Failing the Feasibility Criteria, measured over 3 months.
| Element | Registry entry |
|---|---|
| Result type | N/A |
| Measure of spread | not applicable |
| Unit | not stated |
| Endpoint classification | not reduced to a single comparison |
The primary endpoint was the fraction of participants who could receive E7 TCR T-cell induction therapy without failing the feasibility criteria, assessed over 3 months. In general, a feasibility endpoint evaluates whether a planned treatment process can be delivered under prespecified conditions; it is distinct from an endpoint designed to estimate a treatment’s effect on cancer outcomes.
The registry’s criteria covered delivery of induction therapy without an increase in tumor T or N stage between baseline and the last response assessment before referral for definitive treatment; initiation of definitive therapy without a delay related to induction-therapy toxicity; and receipt of E7 TCR T cells after starting conditioning chemotherapy. Starting the conditioning regimen but not receiving the T cells was to count as a feasibility failure. Failure by any criterion was to count as an overall feasibility failure.
The endpoint description states that the fraction was to be reported with 95% confidence intervals. However, the registry says outcome data were not collected because the sole enrolled participant was a screen failure and did not receive induction therapy. Consequently, the planned fraction and its confidence interval are not available. The endpoint’s intended role can be described, but its performance cannot be estimated from this record.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The central result is that the planned primary feasibility outcome was not measured. The registry reports enrollment of 1, but that participant was deemed a screen failure after signing consent and did not receive induction therapy. The study was terminated. Thus, the posted results do not contain treated-participant observations on whether the therapy could be delivered according to the feasibility criteria.
This distinction matters because enrollment is not the same as treatment exposure. The endpoint concerned participants receiving induction therapy and meeting or failing criteria related to tumor stage, treatment timing, and receipt of cells after conditioning chemotherapy. Since the participant was not treated, the registry explicitly states that data for this outcome measure were not collected. No feasibility fraction or confidence interval is reported.
The record also does not report analyses for the outcome. It contains no estimate of treatment-related delay, no assessment of tumor stage change during induction, and no result concerning completion of the cell-therapy process. The endpoint’s 3-month timeframe describes the planned assessment, not an observed follow-up result in this trial.
The adverse-event record lists zero participants at risk and zero affected for the displayed categories. In context, that does not establish that the treatment had no adverse effects: the enrolled participant did not receive it, and the record does not document treated participants from whom treatment-emergent safety could be assessed. The study’s objective included safety and avoiding delay to standard treatment, but the posted results do not provide evidence to answer those questions.
The study is single-group, and no comparator is recorded. It therefore cannot provide a randomized comparison against standard treatment or another control group. More fundamentally, with no treated participant and no primary outcome data, there is no observed treatment effect or feasibility estimate to interpret. Any planning illustration based on an observed effect should not be mistaken for a trial result; the registry record does not report an observed primary effect on which such a planning interpretation could rest.
These findings describe what the registry record reports about trial conduct and data availability. They do not establish whether E7 TCR T-cell induction therapy is feasible, safe, effective, or ineffective. The absence of an outcome measurement reflects that the study did not reach treatment for the enrolled participant, rather than an observed failure of the therapy’s feasibility criteria.
9. Statistical Methods Explained
Statistical interpretation begins by distinguishing the planned endpoint from an estimable result. The primary endpoint was a fraction: the number of participants meeting the feasibility definition relative to the relevant participants assessed. In general, a fraction is a descriptive summary of how often a specified event occurs in a defined group. Here, the event was successful receipt of induction therapy without failing any listed feasibility criterion. The registry reports that no outcome data were collected, so the fraction cannot be estimated from the posted results.
What would a confidence interval communicate?
In general, a confidence interval describes statistical uncertainty around an estimated quantity under the assumptions of the analysis method. The registry planned to report 95% confidence intervals with the feasibility fraction. Such an interval would have accompanied an observed fraction; it is not itself a substitute for data. Because the outcome was not measured, no fraction or interval is available. It would be inappropriate to interpret the planned confidence level as a precision statement about an unobserved result.
Why does the participant’s screening status matter?
For an endpoint about receiving induction therapy, screening and treatment are different stages of participation. The registry states that the sole enrolled participant signed consent and was later deemed a screen failure, so the participant was unable to receive induction therapy. The endpoint therefore had no treated-participant observation to classify against the criteria. This is not equivalent to recording a treatment failure: the registry’s stated reason for not collecting the outcome was that the participant was not treated.
What do the feasibility criteria capture?
The criteria combine aspects of disease status, treatment scheduling, and intervention delivery. The first concerns whether tumor T or N stage increased before referral for definitive treatment. The second concerns whether toxicity related to induction therapy delayed initiation of definitive treatment. The third treats starting conditioning chemotherapy without receiving the E7 TCR T cells as a feasibility failure. In general, combining such criteria into a single endpoint can give a practical summary of whether a treatment pathway was completed as intended, but it also means that different events can lead to the same overall classification. No participant-level classification was available in this study.
What can a single-group design establish?
In general, a single-group study can describe outcomes among participants receiving an intervention, but it does not provide a concurrent control group for estimating how outcomes would compare under another treatment. This registry record lists a single-group model and no comparator. Even if treated-participant outcomes had been reported, interpretation would have been limited to the observed group and the study’s endpoint definitions. In this record, the lack of treatment exposure and outcome data prevents even a descriptive estimate of the planned feasibility endpoint.
How should safety information be read?
In general, safety summaries depend on defining who was exposed or at risk and what events were observed during the relevant period. The adverse-event record lists zero at risk and zero affected in its displayed categories, while the registry states that the participant was not treated. Those entries do not establish an absence of treatment-related events in an exposed group. The record does not report treated participants from whom the study’s intervention-related safety could be evaluated.
What do the planning illustrations mean?
In general, a sample-size planning illustration explores how many participants might be needed under specified assumptions. The record describes illustrations based on an observed effect, a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; it distinguishes participant counts per arm from total event counts for time-to-event settings. These are planning conventions, not observed trial outcomes or observed power. The record is single-group and reports no primary outcome analysis, so such illustrations do not alter the conclusion that this trial produced no estimated feasibility result. No sample-size justification for the trial itself is reported in the registry record.
Other elements of a statistical analysis plan, including any interim analyses or detailed analysis procedures, are not reported in the registry record. The registry lists no analyses for the outcomes. As a result, interpretation should remain anchored to the descriptive details: the intended endpoint and criteria, the failure to treat the enrolled participant, and the absence of outcome data.
10. Multiplicity, Missing Data and Analysis Populations
The primary endpoint was defined as a single fraction based on a composite feasibility definition, with failure on any listed criterion counting as a feasibility failure. The registry record does not report a multiplicity adjustment or a broader testing strategy for multiple outcomes. It also lists no analyses. Without reported outcome data or analysis results, there are no inferential tests to assess for multiplicity in the posted results. Whether a prespecified multiplicity procedure was planned is not reported in the registry record.
The key data limitation is explicit: the primary outcome measure was not done because the sole enrolled participant signed consent and was later deemed a screen failure, and the participant could not receive induction therapy. The record states that data were not collected for this outcome. This is not a situation in which a measured endpoint value is merely absent from a published summary; the registry says the intended outcome was not performed.
The record does not describe an analysis population, such as a treated group or another defined set of participants, and no analysis is reported. The participant’s screening status is described, but the registry does not provide additional participant-level outcome data. A missing-data method, imputation strategy, or sensitivity analysis is not reported in the registry record. Given that there was no treated participant and no endpoint data, there is no basis in the posted results for evaluating how an analytical method might affect the primary estimate.
The distinction between no data collection and a zero outcome is essential. No feasibility fraction, confidence interval, or adverse-event rate among treated participants is reported. The adverse-event entries showing zero at risk should be read alongside the stated lack of treatment exposure, not as a measured demonstration of no risk.
11. What the Result Does, and Does Not, Mean
The record documents a planned investigation of whether E7 TCR T-cell induction therapy could be delivered without failing specified feasibility criteria and without delaying definitive treatment. It also documents that the trial did not generate a primary feasibility result: the sole enrolled participant was deemed a screen failure and did not receive the intervention. The study’s terminated status and lack of collected outcome data are therefore central to interpreting the record.
This outcome does not show that the treatment pathway succeeded or failed. There was no treated participant to assess against the criteria concerning tumor stage, treatment delay, or receipt of cells following conditioning chemotherapy. Nor does the record provide a measured estimate of safety among treated participants. The endpoint’s planned 3-month timeframe and 95% confidence interval do not imply that a follow-up estimate or interval was obtained.
The record also cannot establish a comparative treatment effect. It describes a single-group study without a comparator, and the planned outcome is feasibility rather than a reported comparison of clinical outcomes. No claim about the intervention’s effectiveness can be drawn from the absence of an endpoint result.
In general, an unobserved endpoint is different from a negative finding. The registry’s explanation is that treatment was not given because the participant was a screen failure, not that the participant received treatment and failed a criterion. The results should therefore be understood as inconclusive about feasibility and safety, rather than as evidence for or against the intervention.
The limits are specific: enrollment was 1, treatment was not administered to the enrolled participant, and the study was terminated. The record does not report a treated cohort, a primary endpoint estimate, or an analysis. Those details bound what can be concluded without implying a result the trial did not produce.
12. Why This Trial Matters Statistically
This trial illustrates why enrollment, treatment exposure, and outcome measurement must be kept distinct when reading clinical research records. Although enrollment is recorded as 1, the participant was later deemed a screen failure and did not receive induction therapy. Because the primary question concerned feasibility of receiving that therapy, enrollment alone could not produce an answer to the endpoint question.
The endpoint also shows how a feasibility measure can combine several stages of a clinical pathway. Its criteria included tumor-stage assessment before definitive treatment, avoidance of a treatment delay related to induction-therapy toxicity, and receipt of the cell product after conditioning chemotherapy had begun. Such criteria can represent practical constraints relevant to a complex intervention. But the registry reports no treated participant who could be evaluated against them, so the planned composite remains unmeasured.
Statistically, the record is a useful reminder that a confidence-interval plan does not guarantee an estimate. The endpoint was intended to include a 95% confidence interval, but the registry reports no outcome data. Precision cannot be assessed in the absence of an observed fraction.
The single-group design and lack of a comparator further define the scope of the intended evidence. The study was designed around feasibility, not a randomized comparison, and the record contains no completed analysis. The findings therefore concern trial conduct and data availability, not comparative efficacy. For readers evaluating clinical evidence, the most informative statistical conclusion is that this record cannot estimate the planned feasibility outcome.
13. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The most consequential limitation is that the study did not produce data for its primary endpoint. The registry explains that the sole enrolled participant signed consent but was later deemed a screen failure and could not receive E7 TCR T cells. As a result, no participant could be classified as meeting or failing the feasibility criteria after treatment.
The small enrollment recorded as 1 and the terminated status limit any assessment of the intended treatment process. No treated cohort is reported, and the primary endpoint’s fraction and planned 95% confidence interval are unavailable. The record also lists no outcome analyses. These limitations prevent estimation of feasibility and prevent assessment of the endpoint’s precision.
The absence of a comparator is inherent in the recorded single-group model. The registry therefore does not support a controlled comparison with standard treatment or another intervention. In addition, the adverse-event record lists zero at risk, consistent with the stated lack of treatment exposure; it cannot establish treatment safety among exposed participants.
Further information about the reasons for termination, any statistical analysis plan, sample-size justification, interim analyses, and methods for missing data is not reported in the registry record. These details should not be inferred from the planned endpoint or the sample-size planning conventions. The available record supports a description of the study’s intended question and its failure to reach treatment, but not an estimate of clinical outcomes.
14. Related Tutorials
15. Related Statistical Calculators
16. Sources
- ClinicalTrials.gov: E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer — NCT04015336.
- Registry record last updated 2022-02-24; status last verified 2022-02.
- Results first posted 2022-02-01.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
17. Record Summary
NCT04015336 is a phase II, single-group study of E7 TCR T-cell induction immunotherapy for stage II and stage III HPV-associated oropharyngeal cancer, focused on HPV-16-associated disease. Its objective was to assess whether induction therapy could be given safely without delaying standard treatment. The planned primary outcome was the fraction of participants who received therapy without failing feasibility criteria over 3 months, with 95% confidence intervals planned.
The registry records enrollment of 1, a terminated status, a start date of 2020-07-06, and primary completion on 2020-07-15. The sole enrolled participant was deemed a screen failure and did not receive induction therapy. The registry states that the primary outcome was not done and data were not collected. No primary outcome estimate or analysis is reported, and the record has no comparator group.